Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing KIMMTRAK®(tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma in light of its recent FDA approval- 2nd look

Ticker(s): IMCR

Who's the expert?

Institution: Keystone Retina Associates

Board-certified ophthalmologist specializing in complex vitreo retinal surgery and medical retinal conditions
Manages 600 patients with wet-AMD, 250 patients with presbyopia, and 500 patients with geograpgic atrophy.
An accomplished clinician, published author, researcher, lecturer, and investigator in national clinical trials studying new therapies for macular degeneration, diabetic macular edema, and retinal vein occlusion. .

Interview Goal

The ideal expert will be knowledgeable about the potential of KIMMTRAK as the first T cell receptor (TCR) therapeutic to receive regulatory approval and familiar with the press releases and clinical trial data surrounding KIMMTRAK. We would like to discuss the potential of this novel therapeutic in the ophthalmology space.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.